Bertalan, Mia

By Michael Hilleary | August 16, 2022

 

 

Mia Bertalan, MD

Portrait photo of Dr. Mia Bertalan

Hometown:

Riverton, WY, USA

Undergraduate School:

Harvard University

Medical School:

Dartmouth Geisel School of Medicine

Bio:

Growing up I wanted to be a vet or biologist. Volunteering with Health Leads in college got me interested in (human) medicine – no surprise to my mom, a nurse who always wanted one of her two kids to be a doctor. Work as a neuro-oncology clinical research and brain donation coordinator before med school got me interested in oncology, which led to my current interest in surgical oncology. I’m excited for the time and opportunities at the UW to explore this interest and gain exposure to other fields within general surgery.

Personal Interests:

Climbing, hiking, Tough Mudders, horseback riding, skiing, yoga, fiddle

Clinical Interests:

Surgical oncology, critical care, global health, quality improvement

Professional Activities:

American College of Surgeons
Association of Women Surgeons
Society of Surgical Oncology
Undersea & Hyperbaric Medical Society
Alpha Omega Alpha

Why UW?

UW is an exciting intersection of volume, breadth, and depth in a variety of clinical settings, including academic, county, VA, pediatric, and level 1 trauma for 5 states. You serve a diverse patient population while working alongside faculty mentors, co-residents, and numerous other health professionals who teach and inspire you every day to become better. No matter what kind of surgeon you strive to be, UW offers the training and support to help you get there.

What advice do you have for incoming interns?

Get to know your patients, especially their goals and priorities.
Make your own learning plan and seek out the opportunities to realize it.
Take care of yourself mentally and physically with appreciation of the fact that self-care can look wildly different for different people.
Always assume best intentions.

What do you like best about living in Seattle?

Having lived in SoCal, the Rockies, the South, and New England, I’m excited to now call the beautiful Pacific Northwest home. I can do all my favorite outdoor activities within an hour drive of this city, and Seattle itself is a diverse and vibrant place with plenty of restaurants, sports, parks, and cultural attractions to pass the time when I’m not working, studying, or sleeping.

Publications:

  1. Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D’Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT. Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. Nature Precision Oncology. 18 September 2017; 1(33), 1-8. PMID: 29872714. doi: 10.1038/s41698-017-0035-9
  2. Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence D, Flaherty K, Shih H, Oh K, Batchelor T, Cahill D, Sullivan R, Brastianos PK. CMET-16. The role of surgical resection of melanoma brain metastases in the immunotherapy era. Neuro-oncology. November 2018; 20(suppl 6), vi56-vi57. doi: 10.1093/neuonc/noy148.228.
  3. Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: Review and update on management. Cancer. January 2018; 124(1), 21-35. PMID: 29165794 doi: 10.1002/cncr.30911
  4. White M, Brastianos PK, Batchelor T, Nayyar N, Gill C, Lastrapes M, Bertalan M, Kaplan A, D’Andrea M, Bihun I, Kaneb A, Dietrich J, Ferry J, Martinez-Lage Alvarez M, Giobbie-Hurder A, Borger DR, Rodriguez FJ, Holdhoff M, Cahill DP, Carter SL. MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas. Journal of Clinical Oncology. 1 June 2018; 36(15_suppl), e14041-e14041. doi: 10.1200/JCO.2018.36.15_suppl.e14041
  5. Strickland MR, Bertalan MS, Kuter BM, Juratli TA, Melchert V, Higgins N, Toups MR, Kaplan A, Bihun I, Nayyar N, Martinez-Lage M, Lastrapes M, Borger DR, Shih HA, Hong TS, Brastianos PK. Whole exome sequencing of brain metastases from colorectal primary cancers reveals clinically actionable mutations. Neuro-Oncology. 5 November 2018; 20(suppl_6), vi56. doi: 10.1093/neuonc/noy148.227
  6. Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG 2nd, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathologica. November 2018; 136(5), 779-792. doi: 10.1007/s00401-018-1899-7
  7. Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence DP, Flaherty KT, Shih HA, Oh K, Batchelor TT, Cahill DP, Sullivan R, Brastianos PK. Upfront surgical resection of melanoma brain metastases provides a bridge towards immunotherapy mediated systemic control. Oncologist. May 2019; 24(5), 671-679. PMID: 30796152. doi: 10.1634/theoncologist.2018-0306
  8. Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, D’Andrea MR, Bihun I, Kaneb A, Dietrich J, Ferry JA, Martinez-Lage M, Giobbie-Hurder A, Borger DR, Rodriguez FJ, Frosch MP, Batchelor E, Hoang K, Kuter B, Fortin S, Holdhoff M, Cahill DP, Carter S, Brastianos PK, Batchelor TT. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Advances.12 Feb 2019; 3(3), 375-383. PMID: 30723112. doi 10.1182/bloodadvances.2018027672
  9. Wang N, Cohen JV, Goss NC, Bertalan MS, Keeley MC, Oh K, Brastianos P. The impact of a dedicated multidisciplinary tumor board on care for patients with brain metastases. Journal of Clinical Oncology. 26 May 2019; 37(15_suppl), e13585. doi: 10.1200/JCO.2019.37.15_suppl.e13585
  10. Fujio S, Juratli TA, Arita K, Hirano H, Nagano Y, Takajo T, Yoshimoto K, Bihun IV, Kaplan AB, Nayyar N, Fink AL, Bertalan MS, Tummala SS, Curry WT Jr, Jones PS, Martinez-Lage M, Cahill DP, Barker FG 2nd, Brastianos PK. A clinical rule for preoperative prediction of BRAF mutation status in craniopharyngiomas. Neurosurgery. 1 August 2019; 85(2), 204-210. PMID: 30481321. doi: 10.1093/neuros/nyy569
  11. Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Castro LNG, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen Orit, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suva ML. An integrative model of cellular states, plasticity and genetics for glioblastoma. Cell, 178(4). 8 August 2019; 178(4), 835-849e21. PMID: 31327527. doi: 10.1016/j.cell.2019.06.024
  12. Wang N, Cohen JV, Goss NC, Bertalan MS, Keeley MC, Parsons M, Nahed B, Cahill D, Oh K, Brastianos P. The impact of a dedicated multidisciplinary tumor board on care for patients with brain metastases. Neuro Oncol, 21(2uppl 6), vi135-vi136. doi: 10.1200/JCO.2019.37.15_suppl.e13585
  13. Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, Bertalan M, Kaplan A, D’Andrea MR, Chukwueke U, Ippen FM, Alvarez-Breckenridge C, Camarda ND, Lastrapes M, McCabe D, Kuter B, Kaufman B, Strickland MR, Martinez-Gutierrez JC, Nagabhushan D, De Sauvage M, White MD, Castro BA, Hoang K, Kaneb A, Batchelor ED, Paek SH, Park SH, Martinez-Lage M, Berghoff AS, Merrill P, Gerstner ER, Batchelor TT, Frosch MP, Frazier RP, Borger DR, Iafrate AJ, Johnson BE, Santagata S, Preusser M, Cahill DP, Carter SL, Brastianos PK. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nature Genetics. April 2020; 52(4), 371-377. PMID: 32203465. doi:10.1038/s41588-020-0592-7
  14. Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. Single-arm, open-label phase 2 trial of pembrolizumab in leptomeningeal carcinomatosis. Nature Medicine. August 2020; 26(8), 1280-1284. PMID: 32483359. doi: 10.1038/s41591-020-0918-0.
  15. Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, Wong ET, Gerstner ER, Dietrich J, Plotkin SR, Norden AD, Lee EQ, Nayak L, Tanaka S, Wakimoto H, Lelic N, Koerner MV, Klofas LK, Bertalan MS, Betensky RA, Curry WT, Borger DR, Balaj L, Kitchen RR, Chakrabortty SK, Valentino MD, Skog J, Breakefield XO, Iafrate AJ, Batchelor TT. Exploring predictors of response to dacomitinib in EGFR amplified recurrent glioblastoma. JCO Precision Oncology. 8 June 2020; 4(1), 593-604. PMID: 32923886. doi: 10.1200/PO.19.00295
  16. White MD, Klein RH, Shaw B, Kim A, Subramanian M, Nagabhushan D, Jain A, Singh M, Mora JL, Kuter BM, Nayyar N, Bertalan M, Stocking JH, Markson SC, Lastrapes M, Alvarez-Breckenridge C, Cahill DP, Gydush G, Rhoades J, Rotem D, Adalsteinsson VA, Keeley M, Kaplan A,Oh K, Sullivan R, Carter SL, Brastianos PK. Detection of leptomeningeal disease using cell-free DNA from cerebrospinal fluid. JAMA Network Open. August 2021; 4(8), e2120040. PMID: 34369989. doi: 10.1001/jamanetworkopen.2021.20040.